Japanese pharmaceutical company Takeda invested over 98 million euros in the production of pharmaceuticals in Russia, 477 million rubles of which were assigned to the production of innovation orphan drug Ixazomib named Ninlaro for patients with multiple myeloma (blood cancer). This information was provided to TASS by a company’s press service representative at the opening ceremony of the drug manufacturing site of the plant in Yaroslavl.
Construction of 450 MW Huadian-Teninskaya CCPP has been completed in Yaroslavl Region Pre-commissioning works have been started at the facility that is expected to reduce the region’s power shortages
Takeda has launched its integrated production of Actovegin in the form of sterile injection solution at its Yaroslavl plant. Thus all forms of the drug (pills and injections solutions) are now produced in Russia.
UEC-Saturn (member of the United Engine Corporation, UEC) and the French Safran Aircraft Engines (member of the Safran Group) concluded a master agreement for development of a modification of the SaM146 engine for remotorization of the Russian amphibian aircraft Be-200. The news was reported by the press-office of UEC.
Besins Healthcare SA will build a new drug manufacturing plant in Yaroslavl Region. The new facility will produce Utrogestan which is included in the Russia's Essential Drugs List. Project investment will account for RUB 500 mln, the launch of commercial production is scheduled for 2019.
Israeli Teva Pharmaceutical Industries, one of the world’s largest drug producers, will double the drug production at its Yaroslavl plant to 500 mln pills in 2016.